Uhlmann Group Spins Off visiotec GmbH - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Uhlmann Group Spins Off visiotec GmbH


An independent subsidiary of Uhlmann Germany, visiotec GmbH, was created on April 1, 2013 to focus on inspection, monitoring, and control systems for automated pharmaceutical manufacturing processes, the company announced in a press release.

The spin-off addresses the pharmaceutical industry’s demand for a more holistic approach beyond the traditional borders of manufacturing and packaging, said the company. Visiotec will provide solutions for product quality and safety using inline monitoring, based on its expertise in process analytical technologies, such as high-speed, near-infrared analysis and advanced mass-verification technology.

Visiotec GmbH will operate globally from offices in Germany, Switzerland, and the United States. The printing, inspection, and track-and-trace products formerly offered by Uhlmann VisioTec GmbH for packaging applications will be handled by the Uhlmann Group’s dedicated Uhlmann Customer Services division.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here